Details der Publikation - A Study exploring the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer (NSCLC)

A Study exploring the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer (NSCLC) : An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC)

Medienart:	Klinische Studie

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	WHO International Clinical Trials Registry Platform - (2023) vom: 21. Juni Zur Gesamtaufnahme - year:2023

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC) MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.1Level: LLTClassification code 10080083Term: Advanced lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04] Phase: Phase 2 Recruitment Status: Not yet recruiting Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 30-04-2018, Last updated: 2023-06-29

ICTRP ID:	EUCTR2018-000462-11-DE CA209-592 NCT03001882

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	CTG004275047

Internformat


LEADER	01000caa a22002652 4500
001	CTG004275047
003	DE-627
005	20230629100623.0
007	cr uuu---uuuuu
008	210507s2023 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)CTG004275047
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2018-000462-11-DE
035			\|a (UBBS_Klinische_Studien_WHO)CA209-592
035			\|a (UBBS_Klinische_Studien_WHO)NCT03001882
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a A Study exploring the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer (NSCLC) \|b An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC)
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 30-04-2018, Last updated: 2023-06-29
650		4	\|a Medical Condition: Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC) MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.1Level: LLTClassification code 10080083Term: Advanced lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 2
650		4	\|a Recruitment Status: Not yet recruiting
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2023) vom: 21. Juni
773	1	8	\|g year:2023 \|g day:21 \|g month:06
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000462-11 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
951			\|a AR
952			\|j 2023 \|b 21 \|c 06

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände